These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3774120)

  • 1. Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion.
    Carlsson M; Eriksson E; Nilsson C; Carlsson A
    Neuropharmacology; 1986 Aug; 25(8):951-4. PubMed ID: 3774120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats.
    Carlsson M; Carlsson A; Eriksson E
    Eur J Pharmacol; 1987 Oct; 142(1):39-43. PubMed ID: 3691635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective inhibition of prolactin secretion by (-)-HW-165, a novel 3-PPP congener; further support for similarities between central DA autoreceptors and pituitary lactotroph DA receptors.
    Hjorth S; Eriksson E; Andersson B
    Eur J Pharmacol; 1986 Jun; 125(3):421-8. PubMed ID: 3755402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland.
    Mikuni M; Gudelsky GA; Simonovic M; Meltzer HY
    Life Sci; 1984 Jan; 34(3):239-46. PubMed ID: 6694521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
    Ekman A; Quiding M; Eriksson E
    Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D; Hjorth S; Carlsson A
    Eur J Pharmacol; 1984 Oct; 106(1):185-9. PubMed ID: 6099268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.
    Eriksson E; Modigh K; Carlsson A; Wikström H
    Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.
    Hjorth S; Svensson K; Carlsson A; Wikström H; Andersson B
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):205-18. PubMed ID: 3762735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion.
    Carlsson M; Eriksson E
    Life Sci; 1988; 42(5):585-8. PubMed ID: 3339950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of two dopamine agonists, TL-99 and 3-PPP, on prolactin secretion in the rat.
    Gudelsky GA; Passaro E; Meltzer HY
    Eur J Pharmacol; 1983 Jun; 90(4):423-5. PubMed ID: 6884430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The partial dopamine receptor agonists (--)-3-PPP and transdihydrolisuride enhance prolactin secretion in female but not in male rats.
    Carlsson M; Eriksson E
    J Neural Transm; 1989; 77(2-3):211-6. PubMed ID: 2569498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
    Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (+/-)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine).
    Kelly TR; Howard HR; Koe BK; Sarges R
    J Med Chem; 1985 Sep; 28(9):1368-71. PubMed ID: 3928893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
    Rollema H; Mastebroek D; Wikström H; Svensson K; Carlsson A; Sundell S
    J Med Chem; 1986 Oct; 29(10):1889-95. PubMed ID: 3761308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.